AKAP4 is a circulating biomarker for non-small cell lung cancer
Metrics: PDF 2398 views | HTML 2296 views | ?
Kiranmai Gumireddy1, Anping Li1, David H. Chang2, Qin Liu1, Andrew V. Kossenkov1, Jinchun Yan3, Robert J. Korst4, Brian T. Nam5, Hua Xu6, Lin Zhang7, Ganepola A.P. Ganepola2,4, Louise C. Showe1, Qihong Huang1
1The Wistar Institute Cancer Center, Philadelphia, PA 19104, USA
2Center for Cancer Research and Genomic Medicine, The Valley Hospital, Paramus, NJ 07652, USA
3University of Washington Medical Center, Seattle, WA 98195, USA
4Department of Surgery, The Valley Hospital, Ridgewood, NJ 07450, USA
5Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, DE 19713, USA
6Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technology, Wuhan 430030, China
7Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, PA 19104, USA
Qihong Huang, e-mail: firstname.lastname@example.org
Keywords: circulating biomarker, cancer
Received: March 13, 2015 Accepted: May 01, 2015 Published: May 13, 2015
Cancer testis antigens (CTAs) are widely expressed in tumor tissues, circulating tumor cells (CTCs) and in cancer derived exosomes that are frequently engulfed by lymphoid cells. To determine whether tumor derived CTA mRNAs could be detected in RNA from purified peripheral blood mononuclear cells (PBMC) of non-small cell lung cancer (NSCLC) patients, we assayed for the expression of 116 CTAs in PBMC RNA in a discovery set and identified AKAP4 as a potential NSCLC biomarker. We validated AKAP4 as a highly accurate biomarker in a cohort of 264 NSCLCs and 135 controls from 2 different sites including a subset of controls with high risk lung nodules. When all (264) lung cancers were compared with all (135) controls the area under the ROC curve (AUC) was 0.9714. When 136 stage I NSCLC lung cancers are compared with all controls the AUC is 0.9795 and when all lung cancer patients were compared to 27 controls with histologically confirmed benign lung nodules, a comparison of significant clinical importance, the AUC was 0.9825. AKAP4 expression increases significantly with tumor stage, but independent of age, gender, smoking history or cancer subtype. Follow-up studies in a small number of resected NSCLC patients revealed a decrease of AKAP4 expression post-surgical resection that remained low in patients in remission and increased with tumor recurrence. AKAP4 is a highly accurate biomarker for the detection of early stage lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.